Drug search by name

Permax and Cardiac valve disease/arrhythmias

Result of checking the interaction of drug Permax and disease Cardiac valve disease/arrhythmias for safety when used together.

Check result:

Permax <> Cardiac valve disease/arrhythmias

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

The use of pergolide has been shown to increase the risk of cardiac valvular disease involving one or more valves. Some patients have required valve replacement, and deaths have been reported. Specific risk factors predisposing patients to developing cardiac valvular disease with pergolide have not been identified. Cardiac valvulopathy has been reported with all doses of pergolide; however, available data suggest that the risk may be greater with higher doses. Pergolide is not recommended for use in patients with a history of cardiac valvulopathy. Additionally, caution should be exercised when administering pergolide to patients prone to cardiac dysrhythmias. Before initiating treatment with pergolide, all patients should undergo a cardiovascular evaluation, including an echocardiogram, to determine whether valvular disease is present and to provide a baseline for subsequent monitoring.

References:

Ahlskog JE, Muenter MD "Treatment of Parkinson's disease with pergolide: a double-blind study." Mayo Clin Proc 63 (1988): 969-78
Lamberts SW, Quik RF "A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia." J Clin Endocrinol Metab 72 (1991): 635-41
Ahlskog JE, Muenter MD "Pergolide: long-term use in Parkinson's disease." Mayo Clin Proc 63 (1988): 979-87
Robin DW "Pergolide in the treatment of Parkinson's disease." Am J Med Sci 301 (1991): 277-80
Pezzoli G, Martignoni E, Pacchetti C, Angeleri VA, Lamberti P, Muratorio A, Bonuccelli U, Demari M, Foschi N, Cossutta E, Nicolet "Pergolide compared with bromocriptine in parkinsons disease - a multicenter, crossover, controlled study." Mov Disord 9 (1994): 431-6
"Product Information. Permax (pergolide)." Athena Neurosciences Inc, South San Francisco, CA.
Olanow CW, Alberts MJ "Double-blind controlled study of pergolide mesylate in the treatment of Parkinson's disease." Clin Neuropharmacol 10 (1987): 178-85

Permax

Generic Name: pergolide

Brand Name:

Synonyms: n.a.

What is Permax?